FDA panel backs female sex pill, but multiple caveats
This article was originally published in Scrip
Executive Summary
A mega FDA advisory panel on 4 June backed approval of a twice-rejected drug aimed at boosting a woman's libido, although the outside advisers want certain restrictions imposed on the product's marketing, including a risk evaluation and mitigation strategy (REMS) plan, to ensure adverse effects, most notably fainting, are properly managed.